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ABSTRACT
Background: Little is known about the safety and effectiveness of early interventional treatment (EIT) with in-
tranasal corticosteroids for seasonal allergic rhinitis. We designed a double-blinded, randomized, placebo-
controlled 12-week trial of EIT with mometasone furoate nasal spray (MFNS) for Japanese cedarcypress polli-
nosis (JCCP).
Methods: A total of 50 JCCP patients received MFNS (200 μg once daily: n = 25) or placebo (n = 25) starting
on February 1, 2010. Treatments continued until the end of April. The primary endpoint was the comparison of
the total nasal symptom score (TNSS) between the MFNS and placebo groups. The secondary endpoints in-
cluded comparisons of QOL, daytime sleepiness, nasal ECP levels, and safety.
Results: Continuous dispersion of Japanese cedar pollen began on February 22. Although the placebo group
showed a significant worsening of symptoms after the start of the continuous dispersion, no worsening oc-
curred in the MFNS group. A significant difference in the TNSS between the two groups was seen starting at 4
weeks after the treatment. Similar results were seen for QOL and sleepiness. Nasal ECP levels in March were
significantly lower in the MFNS group. A total of 56% of the MFNS group progressed to a persistent allergic
rhinitis state in accordance with the ARIA classification, as opposed to 84% of the placebo group. MFNS was
well tolerated, and the plasma cortisol concentrations were similar between the two groups.
Conclusions: EIT with MFNS for JCCP is both safe and effective. This treatment can potentially lessen symp-
toms and help pollinosis patients remain in the intermittent state.
KEY WORDS
early interventional treatment, ECP, intranasal corticosteroids, Japanese cedarcypress pollinosis, total nasal
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INTRODUCTION
Allergic rhinitis (AR) is a global healthcare problem
that greatly affects daily activity, work productivity,
learning, sleep, and the quality of life (QOL).1 The
prevalence of AR has continued to rise over the past
decade, with rates in Japan increasing from 29.8% in
1998 to 39.4% in 2008.2
The major AR phenotype in Japan is the Japanese
cedarcypress pollinosis (JCCP), which has a preva-
lence of 26.5%.2 JCCP is mainly due to exposure to
Japanese cedar (Cryptomeria japonica) and Japanese
cypress (Chamaecyparis obtuse) pollen.3 Dispersal of
the cypress pollen in the spring occurs after that for
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cedar pollen. Since cedar pollen and cypress pollen
contain several cross-reactive components, the
pollinosis-related symptoms can therefore last for as
long as 4 months, being present from February until
early May in some subjects.4,5 In addition, dispersion
of Asian sand dust during the same season is also
thought to exacerbate JCCP.6
Initial dispersion of the pollen can have a priming
effect and cause a minimal persistent inflammation
that is characterized by an influx into the nasal mu-
cosa of inflammatory cells such as eosinophils. These
conditions lead to allergen and non-specific irritant
hypersensitivities, which contribute to the onset of
AR.1,7 Therefore, the Practical Guideline for the Man-
agement of Allergic Rhinitis in Japan (PG-MARJ) rec-
ommends that patients who annually experience sub-
stantial symptoms of pollinosis should receive early
interventional treatment (EIT, or in other words pro-
phylactic or initial treatment) starting immediately af-
ter pollen release or the onset of symptoms. The PG-
MARJ recommends that physicians determine the
drug regimen for individual patients based on the
amount of expected pollen release during the season
and the type and severity of symptoms that are usu-
ally experienced by each patient during the peak pol-
len season. Treatments need to be selected from
among chromones, second-generation H1-receptor
antagonists (H1RA), leukotriene receptor antago-
nists, Th2 cytokine suppressor (suplatast) and the
PGD2TXA2 receptor antagonist (ramatroban) for
EIT.2 In contrast, the international guideline for AR,
ARIA, recommends oral or topical H1RA, topical de-
congestants, topical chromones or nasal douching
with saline for mild intermittent AR, which may be
representative of early stage pollinosis.1
Intranasal glucocorticosteroids (INS) are the most
effective drugs for controlling AR-caused inflamma-
tion, with the mechanism of action for these drugs us-
ing at least two pathways, the transactivation and the
transrepression pathways.8 As such, INS can control
both the priming effect and the minimal persistent in-
flammation, and thus can potentially be used as EIT
for pollinosis.7 There has only been one significant
report that has investigated the efficacy of INS when
used as EIT for pollinosis.9
Mometasone furoate nasal spray (MFNS) is one of
the new generation INS that have a minimal bioavail-
ability, thus, potentially making it fit for use as an EIT
for pollinosis.10 Recent meta-analysis has demon-
strated level 1a evidence for the efficacy of MFNS in
AR treatment versus placebo.11 This previous review
analyzed 16 articles that were published from 1966 to
October 2007 and met the criteria for double-blinded,
randomized, and placebo-controlled clinical trials
(DB-RCT). Of these, 12 of the studies included polli-
nosis patients. However, the patients in most of the
studies had already acquired substantial symptoms,
and in addition, were only observed over a short pe-
riod of time (from a single dose to 4 weeks). There
was only one DB-RCT study conducted over an 8-
week period that showed the efficacy and safety of
MFNS as EIT for ragweed pollinosis.9 However,
since there have been no DB-RCT in Japan that have
evaluated the efficacy and safety of INS as EIT for
JCCP, we decided to perform a 12-week DB-RCT of
EIT using MFNS for JCCP. The results presented
here include information not only on the efficacy, in-
cluding for the naso-ocular symptoms and QOL, but
also provide safety profile information with regard to
the MFNS plasma cortisol levels when used as EIT in
pollinosis. These experimental results demonstrate
for the first time that EIT with MFNS can potentially
control the intermittent state and prevent worsening
of pollinosis in patients that otherwise might lead to a
persistent state.
METHODS
PATIENTS
Inclusion criteria for the JCCP subjects enrolled in
the study were: (a) male or female between the age of
16 and 65 years; (b) at least a 2-year history of JCCP;
(c) sensitization to Japanese cedar pollen as assessed
by a skin prick test; and (d) ability to accurately fill in
diary cards. Patients were excluded from the study if
they had: (a) concomitant sinonasal disease that
could potentially affect the outcome of the trial (e.g.,
nasal polyps, rhinosinusitis, nasal septum deviation);
(b) concomitant treatment for AR caused by allergens
other than Japanese cedarcypress pollen; (c) rhinitis
medicamentosa and non-infectious, non-allergic rhini-
tis; (d) cedar pollen-specific immunotherapy; (e) si-
nonasal surgery including laser vaporization of infe-
rior turbinates within 1 year; (f) medication with anti-
allergic drugs including H1RA, chromones, glucocor-
ticoids and decongestants within 2 weeks of study in-
itiation; (g) hypersensitivity to MFNS; (h) systemic
infection including mycosis; or (i) were pregnant and
breastfeeding.
STUDY DESIGN
The study was a single-center, double-blinded, ran-
domized, placebo-controlled, two-parallel group trial
that was carried out from 2009 to 2010. The primary
endpoint was the comparison of MFNS and placebo
total nasal symptom scores (TNSS) that were ob-
tained from diary cards filled out between February
and April 2010. The secondary endpoints were com-
parisons of the total ocular symptom scores (TOSS),
total symptom score (the sum of TNSS and TOSS:
T5SS), QOL, daytime sleepiness, smell disturbance,
frequency of use of rescue medication, ECP levels in
nasal secretions, and safety, which included plasma
cortisol levels.
Screening visits were performed in December 2009
and continued until a total of 50 patients fulfilled the
inclusion criteria. Prior to study initiation, we esti-
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mated the sample size that would be required based
on the mean and standard deviation in the groups re-
ported for a previous study.12 In order to yield an 80%
study power for the mean and standard deviation val-
ues (1.1+-1.1, 2.1+-1.1) of the INS and placebo
groups, a total of 20 subjects were required for the
primary endpoint of the symptom score from the do-
mestic clinical data (when using a 2-sided Student’s t-
test with α = 0.05).12 Based on these calculations, we
determined that a sample size of 25 subjects per each
group would be necessary when assuming there
would be a 20% drop-out rate.
Patients were randomized and received either
MFNS (100 μg per nostril once daily in the morning)
or placebo during the 12-week double-blind phase.
The inactive placebo contained benzalkonium chlo-
ride and phenylethyl alcohol, identically concentrated
to active MFNS, in saline. Smell and appearance of
device between MFNS and placebo were same. Allo-
cation concealment was granted by the central regis-
try and computer-generated block randomization. Af-
ter the randomization, patients came in for a second
visit in January 2010, so that the MFNS or placebo,
diary cards with written instructions, the Japanese rh-
inoconjunctivitis quality-of-life questionnaires (JRQLQ),
the Japanese edition of Epworth Sleepiness Scale
(JESS) and the self-administered odor questionnaire
(SOQ) could be distributed to each of the sub-
jects.13-15 During the patient visit, the investigator ex-
plained how to accurately fill in the diary card and
questionnaires. The investigator also instructed each
of the patients on how to correctly use the spray. Af-
ter blood and nasal samples were collected at the sec-
ond visits, the patients then started to fill in their di-
ary cards.
Starting on February 1, patients began to receive
either the MFNS or the placebo. Treatments contin-
ued for 12 weeks and finished at the end of April. Pa-
tients were allowed to use loratadine provided and
eye drops as rescue medications on demand. JRQLQ,
JESS and SOQ were filled every other week for a total
of seven times (February 1 and 15, March 1, 15 and
29, and April 12 and 26). Patients returned for a visit
every month in order to confirm the accuracy of their
filling in the diaryquestionnaires, to assess the oc-
currence of adverse events, and to collect blood and
or nasal samples. The study was approved by the In-
stitutional Review Board of Okayama University
Graduate School of Medicine, Dentistry and Pharma-
ceutical Sciences (Rinri-751), and registered in UMIN
(UMIN000005985). Prior to participation in the study,
all patients provided written informed consent.
DIARY CARDS
The patients’ diary contained reports on the presence
and intensity of three nasal symptoms (sneezing, rhi-
norrhea, and nasal congestion), and two ocular symp-
toms (watery and itchy eyes), along with information
on any impairment of their daily life. Nasal and ocular
symptoms were rated using a 5-point scale that
ranged from 0 to 4 (0 = no symptoms, 1 = minimal,
well tolerated symptoms, 2 = bothersome but toler-
ated symptoms, 3 = severe and hard to tolerate symp-
toms, and 4 = severest symptoms) according to PG-
MARJ.2 The TNSS, TOSS, and T5SS were calculated
by adding the three nasal, two ocular, and five naso-
ocular symptom scores, respectively. Mean weekly
values of TNSS, TOSS, and T5SS were also calculated
for the statistical analysis. Patients also recorded the
use of loratadine and other drugs in their diary, and
this was used to calculate the percentage of patients
using loratadine and the dosage of loratadine for each
week. In accordance with the ARIA classification,
each subject group was further divided into intermit-
tent or persistent state groups based on the presence
of the nasal symptoms recorded in the diaries during
the 12-week period.1 Briefly, patients exhibiting nasal
symptoms fewer than 4 days a week or for less than 4
weeks between February and April were placed in
the intermittent state group. Patients exhibiting nasal
symptoms more than 4 days a week and for more
than 4 weeks during the study period were placed in
the persistent state group.
NASAL ECP LEVELS
Nasal secretions were collected using filter paper.
Two filter paper discs packed in a commercial nasal
provocation kit (Torii Co., Tokyo, Japan) were placed
on the surface of the inferior turbinates for 5 min. Af-
ter the harvest, these discs were then placed into a
1.5 ml micro test tube (Eppendorf AG, Hamburg,
Germany), and stored at -80℃ until assayed.
The discs were soaked with 0.8 ml of Dulbecco’s
phosphate buffered saline (Invitrogen, Grand Island,
NY, USA) overnight at 4℃ with gentle rotation. ECP
levels were determined by using Unicap ECP
(Phadia, Uppsala, Sweden). The detection limit of the
assay was 2 ngml. All results were normalized to the
total protein content in the extracts as determined by
the bicinchoninic acid assay (Pierce, Rockford, IL,
USA).
PLASMA CORTISOL CONCENTRATION
Blood was sampled between 9 and 11 am at the sec-
ond (January 2010) and at the final (May 2010) visit,
with the plasma cortisol concentrations then deter-
mined. The reference range for the morning serum
samples for healthy individuals is 8-25 μgdl.
MEASUREMENT OF POLLEN DISPERSION
Daily Japanese cedar and Japanese cypress pollen
counts were performed using Durham samplers that
were installed on the rooftops of the Okayama Uni-
versity Hospital buildings. The first day of the major
pollen period was defined as the first of 2 consecutive
days where1 graincm2 were counted.16
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Fig.　1　Fluctuation of cedar and cypress pollen dispersion 
in 2010. The open squares and closed circles represent the 
cedar and cypress pollen counts, respectively.
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Table　1　Patient demographics and clinical characteristics
Demographic MFNS (n = 25) Placebo (n = 25) P-Value
sex male 15 15 N.S.†
female 10 10
age (year) range 19-39 19-47 N.S.‡
mean +/- S.D. 26.6 ± 6.2 28.5 ± 8.5
disease duration N.S.‡
1 year  0  0
1 year≤ <3 year  1  0
3 year≤ 20 24
unclear  4  1
severarity of JCCP
during past season N.S.‡
severest  9  9
severe 11 11
moderate  4  4
mild  0  1
unclear  1  0
N.S., not statistically signifi cant. †Fisher’s exact test. ‡Mann-Whitney’s U-test.
STATISTICAL ANALYSIS
Values were expressed as the mean ± SEM for each
subject group. Efficacy analyses were performed with
the intent of population treatments in the future. A
non-parametric Mann-Whitney’s U-test was used to
compare the data between groups, while the Wil-
coxon signed-rank test was used for analysis within
the groups. The percentage of patients using lorata-
dine and the percentage in the intermittent or persis-
tent states, along with the number of patients with ad-
verse effects were compared using Fisher’s exact
probability test. Statistical analyses were performed
using SAS (Statistical Analysis System) version 9.2,
with P < 0.0.5 considered to be significant.
RESULTS
PATIENT POPULATION
Out of the 66 patients that were screened, a total of 50
patients fulfilled the inclusion criteria. After enroll-
ment in the study, patients were randomized to one of
two treatment medications, with 25 receiving MFNS,
200 μg once daily and 25 receiving placebo. All of the
patients completed the study and there were no drop-
outs. The treatment groups were comparable with re-
spect to demographic characteristics, which included
age, sex, disease duration, and severity of JCCP (Ta-
ble 1).
FLUCTUATION OF CEDAR AND CYPRESS POL-
LEN DISPERSION
During 2010, the first dispersion of the Japanese ce-
dar pollen occurred on February 4, with major con-
tinuous dispersion beginning on February 22. The
highest cedar dispersion was seen on March 12, with
18.5 grainscm2day. The first dispersion of cypress
pollen occurred on March 20, with major continuous
dispersion beginning on April 4. The highest cedar
dispersion was seen on April 20, with 67.0 grains
cm2day. The total cedar and cypress pollen count
during the study period was 107.3 and 267.0 grains
cm2, respectively (Fig. 1).
PRIMARY ENDPOINT EFFICACY
Once there was continuous dispersion of Japanese ce-
dar pollen, the placebo group began to display a sig-
EIT with INS in Pollinosis
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Fig.　2　Weekly refl ective total nasal symptom score (TNSS: A), total ocular symptom score (TOSS: B), and total naso-ocular 
symptom score (T5SS: C) from the baseline through 12 weeks after the start of either MFNS treatment (circle) or placebo (trian-
gle). Results are expressed as mean ± SEM. Mann-Whitney’s U-test was used to compare data between the groups (†p < 0.05, 
††p < 0.01). The Wilcoxon signed-rank test was used for analysis within the groups (*p < 0.05, **p < 0.01, ***p < 0.005). Arrow 
shows the beginning of continuous pollen dispersion.
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Fig.　3　Plots of biweekly refl ective QOL, as determined by JRQLQ (A), sleepiness, as determined by JESS (B), and smell dis-
turbance, as determined by SOQ (C). Data were collected and analyzed from baseline until 12 weeks after initiation of treatment 
with MFNS (circle) or placebo (triangle). Results are expressed as mean ± SEM. Mann-Whitney’s U-test was used to compare 
data between the groups (†p < 0.05). The Wilcoxon signed-rank test was used for analysis within the groups (*p < 0.05). Arrow 
shows the beginning of continuous pollen dispersion.
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nificant exacerbation of the nasal symptoms, as
shown by the changes in the TNSS from baseline.
With the exception of 1 week (from April 5 to 11) this
significant exacerbation lasted until the end of the
study, which included the Japanese cypress pollen
dispersion period. However, no significant exacerba-
tion was noted in the group receiving MFNS until the
very end of the study. As compared with the placebo
group, there were significantly lower TNSS seen after
the continuous pollen dispersion in the MFNS group
(Fig. 2A).
SECONDARY ENDPOINT EFFICACY
Similar to the TNSS, ocular symptoms used to deter-
mine the TOSS were significantly exacerbated in the
placebo group but not in the MFNS group after the
continuous dispersion. However, there was no signifi-
cant difference between the two groups for the TOSS
(Fig. 2B). Naso-ocular symptoms determined by
T5SS were also significantly exacerbated in the pla-
cebo group, although this was not observed in the
MFNS group. As compared to the placebo group,
there was a significantly lower T5SS seen in the
MFNS group once there was continuous pollen dis-
persion (Fig. 2C).
From February 1 through April 26, patients filled
out the JRQLQ every other week (a total of seven
times) in order to monitor their QOL. As compared to
the placebo group, there was a significant reduction
in the total QOL score at 4 weeks after starting the
treatment in the MFNS group, which indicates a
good QOL in these patients (Fig. 3A). Similarly, day-
time sleepiness and smell disturbance were moni-
tored by using the JESS and SOQ, respectively. A sig-
Makihara S et al.
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Fig.　4　Comparison of biweekly usage of loratadine as a rescue medication between EIT treatment with MFNS 
(circle) and placebo (triangle). Percentage of patients taking loratadine (A) and dosage of loratadine (B) were 
calculated from the diary cards collected from baseline until 12 weeks after initiation of treatment. Results are ex-
pressed as mean ± SEM. Mann-Whitney’s U-test was used to compare the data between the groups (†p < 0.05). 
The Wilcoxon signed-rank test was used for analysis within the groups (*p < 0.05, **p < 0.01). Arrow shows the 
beginning of continuous pollen dispersion.
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Fig.　5　Comparison of nasal ECP levels between EIT treat-
ment with MFNS (closed bar) and placebo (open bar). Nasal 
secretions were collected by fi lter paper in mid March and 
mid April. Results are expressed as mean ± SEM. P values 
were determined by using Mann-Whitney’s U-test.
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nificant exacerbation of sleepiness from baseline was
noted in the placebo group between March 15 and 29.
This deterioration was not seen in the MFNS group,
although no significant difference was seen between
the two groups throughout the study period (Fig. 3
B). In contrast, there was no change from the base-
line for the smell disturbance for either the MFNS or
placebo group, although the difference between the
two groups was significant at baseline (p = 0.041, Fig.
3C).
Patients were allowed on-demand use of loratadine
during the study period. With the exception of during
March, the percentage of patients taking loratadine in
the MFNS groups after the pollen dispersion was
lower than that in the placebo group, although the dif-
ference was not statistically significant (Fig. 4A). In
addition, the dosage of loratadine was also lower in
the MFNS group, with the difference becoming sta-
tistically significant during the last 2 weeks of April
(Fig. 4B).
EFFICACY OF MFNS BASED ON THE ARIA
CLASSIFICATION
In accordance with the ARIA classification scheme,
patients were classified as having intermittent or per-
sistent rhinitis based on the number of days with na-
sal symptoms present during the 12-week period be-
tween February and April. While 84% of the placebo
group were classified as having persistent rhinitis,
only 56% of the MFNS group met the ARIA classifica-
tion criteria (p = 0.062; Fisher’s exact probability
test).
EFFECT OF MFNS ON NASAL ECP LEVELS
ECP levels in the nasal secretions in mid March were
significantly lower in the MFNS group as compared
to the placebo group (p = 0.031). While there was also
a reduction of the ECP levels in the MFNS group in
mid April, this difference was not statistically signifi-
cant (p = 0.063) (Fig. 5).
SAFETY
Both the treatments were well-tolerated, and had a
similar safety profile (Table 2). While there were nine
and eight adverse events reported in the patient dia-
EIT with INS in Pollinosis
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Fig.　6　Comparison of plasma cortisol levels between EIT 
treatment with MFNS and placebo. Blood samples were col-
lected during the morning in January (baseline) and in May 
(after treatment). Bar represents the mean value. P values 
were determined by using Mann-Whitney’s U-test (between 
groups) and the Wilcoxon signed-rank test (within groups).
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Table　2　Adverse events that were reported during the study regardless of the relationship to the treatment
Adverse events MFNS (n = 25)7 subjects (9 events)
Placebo (n = 25)
8 subjects (8 events)
common cold 5 5
cough 1 1
poor physical condition 1 1
epistaxis 2 0
headache 0 1
ries in the MFNS and placebo group, respectively,
none of the events caused any of the patients to drop
out of the study. In most cases, these adverse events
were related to a common cold and considered to be
unrelated to the treatment.
Plasma cortisol concentrations were similar be-
tween the two groups before and after the study. In-
terestingly, the cortisol levels did not decrease but in-
stead, there was a significant increase after the 12th
week of the trial for both the placebo and the MFNS
groups (Fig. 6).
DISCUSSION
Glucocorticoids anti-inflammatory effect is due to the
down-regulation of the pro-inflammatory genes via
several mechanisms, including the protein-protein in-
teractions that sequester protein kinase A and CREB-
binding protein from NF-κB.17,18 The interaction be-
tween NF-κB, CREB, and the CREB-binding protein
leads to the acetylation of chromatin and the subse-
quent transcription of proinflammatory genes, such
as the genes encoding cytokines, inflammatory en-
zymes, adhesion molecules, and inflammatory recep-
tors.19 Thus, as compared to post-onset treatments,
EIT with INS may be more effective in controlling
pollinosis due to lower activity of NF-κB in the nose
during the early exposure to pollens. In addition,
when there is exposure to a low pollen count, EIT
with INS may have clinically beneficial effects on the
minimal persistent inflammation, a time when nasal
inflammation is present prior to the initial onset of al-
lergic symptoms.7,20
To the best of our knowledge, there have only
been two other randomized studies that have investi-
gated the efficacy of using INS for EIT.9,21 Graft et al.
performed an 8-week DB-RCT for ragweed pollinosis,
and showed that the proportion of minimal symptom
days was significantly higher in both the MFNS and
in the beclomethasone dipropionate groups when
compared with a placebo group.9 Pitsios et al. investi-
gated an open-labeled trial, and reported that when
patients with pollinosis due to grass, parietaria and
or olive trees received MFNS starting 2 to 4 weeks
prior to the pollen season, these patients had more
days without symptoms, a lower TNSS, and were
more satisfied with the treatment as compared to
those patients who were treated with nedocromil so-
dium.21 The reason why we selected MFNS in the
present study was safety such as the extremely low
bioavailability because patients were planned to re-
ceive MFNS for 12 weeks.10
Results of the present study demonstrated that as
compared to placebo, EIT with MFNS significantly al-
leviated nasal and naso-ocular symptoms, improved
the QOL, decreased the dosage of loratadine that had
to be taken as a rescue medication, and decreased
the ECP nasal secretion levels in JCCP. Similar
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trends were seen for the ocular symptoms and sleepi-
ness, although the differences between the two
groups did not reach a level of significance. In par-
ticular, both nasal and ocular symptoms remained
around baseline levels throughout the pollen disper-
sal period in the MFNS group, whereas the symp-
toms were significantly exacerbated in the placebo
group. When taken together with the other findings,
such as the similarity of the frequency of adverse
events between the two groups, and the fact that
there were no dropouts or any decreased plasma cor-
tisol levels in both of the groups, the present findings
may provide additional evidence that EIT with MFNS
can be effectively and safely used to treat JCCP.
Although AR is not a life-threatening disease, it
substantially impairs the QOL.1 Several DB-RCTs
have shown that INS can effectively reduce the QOL
impairments that are associated with AR.22,23 Meltzer
et al. reported that a 4-week treatment with MFNS in
perennial AR patients significantly improved the
QOL, as monitored by the Rhinoconjunctivitis Quality
of Life Questionnaire-Standard (RQLQ-S).22 Bairadini
et al. also showed that a 4-week treatment with
MFNS in patients with persistent AR concomitant
with intermittent asthma improved the QOL, as moni-
tored by the Rhinasthma questionnaire.23 In a recent
systematic review, it was clearly demonstrated that
fluticasone furoate nasal spray not only improved the
nasal symptoms but also the ocular symptoms and
QOL.24 In contrast, Craig et al. demonstrated that an
8-week treatment with topical nasal fluticasone in the
perennial AR patients did not lead to any significant
improvement of the QOL, as monitored by the
RQLQ.25 Our current findings are consistent with the
former reports, and suggest that EIT with MFNS fol-
lowing the exposure to pollen can prevent exacerba-
tions of the QOL in JCCP patients.
Sleep disturbance is commonly observed in con-
gested subjects, and can lead to daytime sleepi-
ness.26,27 In the present study, TNSS and JESS was
correlated significantly (p = 0.019) and positively (ρ =
0.332, by Spearman’s correlation coefficient by rank
test) in mid March. Leukotriene receptor antagonists
and INS have both been reported to improve sleep
disturbance and daytime sleepiness.28-30 For example,
Meltzer et al. demonstrated that a 4-week treatment
with MFNS improved the ESS from 12.5 to 10.6,
whereas there was no significant improvement seen
with the placebo treatment (13.3 to 13.7).30 When we
used the JRQLQ and JESS for estimations in the pre-
sent study, significantly impaired sleep disturbance
and daytime sleepiness was noted in the placebo
group following the pollen dispersion, whereas there
was no deterioration noted throughout the study pe-
riod for the MFNS group. These results are consis-
tent with previous reports, and suggest that control of
minimal persistent inflammation by EIT with MFNS
can prevent sleep-related disturbances that follow pol-
len exposure.
Nasal ECP levels have been shown to increase fol-
lowing allergen exposure, and are considered to be
one of the biomarkers that reflect allergic inflamma-
tion in the nose.31,32 Several reports have also demon-
strated that INS can reduce nasal ECP levels.33,34 In
addition, Wand et al. recently reported that nasal ECP
levels were one of the biomarkers noted during INS
treatment in AR patients.35 The present findings were
consistent with these previous reports, and suggest
that the reason why EIT with MFNS is so effective for
JCCP might be related to its ability to control eosino-
philic inflammation in the nose. Collection of nasal
lavage fluid is a popular method to determine nasal
ECP levels.31,36 In the present study, we chosen pa-
per disc method since this method seems to be sim-
ple and painless as compared to the lavage method. It
is important to investigate a correlation of nasal ECP
levels between the two methods in the future.
EIT with MFNS alleviated ocular symptoms as
compared to placebo. It is known that INS is effective
for not only nasal but also ocular symptoms of sea-
sonal allergic rhinitis.37 A reduction of excess stimu-
lation of naso-ocular reflex and an improvement of na-
solacrimal ducts drainage by controlling nasal inflam-
mation may contribute to the efficacy of INS on ocu-
lar symptoms.37,38
Since JCCP can last from February until May, we
performed a 12-week DB-RCT that covered almost
the entire pollen season. Using this time period en-
abled us to investigate whether EIT with MFNS
could modify the state of pollinosis in accordance
with the ARIA guidelines.1 Despite the fact that the
2010 total pollen count was much lower (374.3
grainscm2) than the average counts observed from
2000 to 2009 (3,546.6 grainscm2), 84% of our placebo
group progressed to the persistent state. On the
other hand, only 56% of the MFNS group progressed
to the persistent state, with the remainder of the sub-
jects continuing to be classified as intermittent state.
This is first time that experimental data has been able
to show that EIT with INS can prevent the progres-
sion of patients with pollinosis to the persistent state
along with being able to help control patient condi-
tions so that they remain within the intermittent state.
However, even though our study was able to docu-
ment this, the differences observed between the
groups did not reach statistically significant levels.
This was most likely due to the sample size in the
current study andor the lower than average pollen
counts. Future studies with larger sample sizes and
or with elevated pollen counts will need to be under-
taken in order to confirm this clinically critical effect.
Morning plasma cortisol concentrations were simi-
lar between the MFNS and placebo groups for both
the pre-seasonal and post-seasonal samples. This re-
sult reflects the finding that the systemic bioavailabili-
ties seen after the intranasal administrations with
EIT with INS in Pollinosis
Allergology International Vol 61, No2, 2012 www.jsaweb.jp 303
mometasone were less than 1%, which suggests that
continuous usage of MFNS at a standard dose for 12
weeks in non-pediatric, non-elderly Japanese does not
affect the hypothalamic-pituitary-adrenal axis.10 When
taken together with the findings that there were no
differences for the incidence of the adverse events
between the two groups, the present study confirms
the previously reported meta-analysis, and suggests
that EIT with MFNS is both well-tolerated and safe to
administer in humans.11
Interestingly, plasma cortisol levels increased after
administration of not only MFNS but also placebo.
Seasonal variation in plasma cortisol levels is known,
and the present result consists with the report by
Hoekstra et al. showing that higher level of the corti-
sol levels was seen in March-May in allergic asthmat-
ics.39 In addition, it is known that exposure to day-
light can affect plasma cortisol levels.40 Thus, irre-
spective of MFNS administration, a significant higher
concentration of plasma cortisol in May as compared
with January may reflect a seasonal variation due to
an increased exposure to daylight.
In conclusion, EIT that uses 200 μg of MFNS once
daily is both effective and safe for treating JCCP. In
particular, EIT with MFNS maintained the levels of
both the symptoms and the QOL at baseline values
throughout almost the entire pollen season. As such,
this ultimately prevented the progression to the per-
sistent state and made it possible to control and main-
tain these pollinosis patients at the intermittent state.
However, since the cedar and cypress pollen disper-
sal in 2010 was lower than average, further investiga-
tions at higher pollen dispersion levels will be re-
quired in order to confirm the margin of efficacy for
this treatment. These studies are currently being un-
dertaken.
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